|
PL2872485T3
(pl)
|
2012-07-13 |
2021-05-31 |
Wave Life Sciences Ltd. |
Asymetryczna grupa pomocnicza
|
|
KR102213609B1
(ko)
|
2012-07-13 |
2021-02-08 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
BR112016016400A2
(pt)
|
2014-01-16 |
2017-10-03 |
Wave Life Sciences Ltd |
Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
|
|
IL320434A
(en)
|
2015-07-22 |
2025-06-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods
|
|
CN108779132B
(zh)
|
2016-03-13 |
2022-04-15 |
波涛生命科学有限公司 |
用于亚磷酰胺和寡核苷酸合成的组合物和方法
|
|
JP2019520339A
(ja)
|
2016-06-03 |
2019-07-18 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド、その組成物および方法
|
|
WO2017220751A1
(en)
|
2016-06-22 |
2017-12-28 |
Proqr Therapeutics Ii B.V. |
Single-stranded rna-editing oligonucleotides
|
|
CN110352244B
(zh)
|
2016-09-01 |
2023-03-21 |
ProQR治疗上市公司Ⅱ |
化学修饰的编辑rna的单链寡核苷酸
|
|
US11873316B2
(en)
|
2016-11-23 |
2024-01-16 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
CA3065523A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
JP2020522510A
(ja)
|
2017-06-02 |
2020-07-30 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
US11718638B2
(en)
|
2017-06-21 |
2023-08-08 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
EP3664816A4
(en)
|
2017-08-08 |
2021-05-19 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
|
|
CA3072110A1
(en)
|
2017-09-18 |
2019-03-21 |
Wave Life Sciences Ltd. |
Technologies for oligonucleotide preparation
|
|
EP3694530A4
(en)
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
SG11202009877XA
(en)
|
2018-04-12 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
US12391942B2
(en)
|
2018-05-11 |
2025-08-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
JP2022525541A
(ja)
|
2019-03-20 |
2022-05-17 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド調製に有用な技術
|
|
TWI866002B
(zh)
*
|
2021-12-29 |
2024-12-11 |
財團法人生物技術開發中心 |
反義寡核苷酸及其用途
|
|
EP4479535A1
(en)
|
2022-02-14 |
2024-12-25 |
ProQR Therapeutics II B.V. |
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
JP2025524566A
(ja)
|
2022-07-15 |
2025-07-30 |
プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ |
Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用
|
|
US20260027237A1
(en)
|
2022-07-15 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Chemically modified oligonucleotides for adar-mediated rna editing
|
|
GB202215614D0
(en)
|
2022-10-21 |
2022-12-07 |
Proqr Therapeutics Ii Bv |
Heteroduplex rna editing oligonucleotide complexes
|
|
WO2024110565A1
(en)
|
2022-11-24 |
2024-05-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
|
|
GB202218090D0
(en)
|
2022-12-01 |
2023-01-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
|
|
AU2023390632A1
(en)
|
2022-12-09 |
2025-07-10 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
GB202300865D0
(en)
|
2023-01-20 |
2023-03-08 |
Proqr Therapeutics Ii Bv |
Delivery of oligonucleotides
|
|
WO2024175550A1
(en)
|
2023-02-20 |
2024-08-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
|
|
EP4689110A1
(en)
|
2023-03-24 |
2026-02-11 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
GB202304363D0
(en)
|
2023-03-24 |
2023-05-10 |
Proqr Therapeutics Ii Bv |
Chemically modified antisense oligonucleotides for use in RNA editing
|
|
EP4688143A1
(en)
|
2023-03-27 |
2026-02-11 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
TW202516003A
(zh)
|
2023-06-16 |
2025-04-16 |
荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ |
用於治療神經退化性疾病之反義寡核苷酸
|
|
AU2024315297A1
(en)
*
|
2023-08-01 |
2026-02-12 |
Tuojie Biotech (Shanghai) Co., Ltd. |
Dsrna targeting mapt and pharmaceutical use thereof
|
|
WO2025051946A1
(en)
|
2023-09-07 |
2025-03-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2025104239A1
(en)
|
2023-11-16 |
2025-05-22 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of classic galactosemia
|
|
WO2025132708A1
(en)
|
2023-12-20 |
2025-06-26 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2026022136A1
(en)
|
2024-07-23 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2026060374A2
(en)
|
2024-09-16 |
2026-03-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
WO2026068781A1
(en)
|
2024-09-30 |
2026-04-02 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|